Literature DB >> 18304681

The management of portal hypertension: rational basis, available treatments and future options.

Jaime Bosch1, Annalisa Berzigotti, Juan Carlos Garcia-Pagan, Juan G Abraldes.   

Abstract

Variceal bleeding is the last step in a chain of events initiated by an increase in portal pressure, followed by the development and progressive dilation of varices until these finally rupture and bleed. This sequence of events might be prevented - and reversed - by achieving a sufficient decrease in portal pressure. A different approach is the use of local endoscopic treatments at the varices. This article reviews the rationale for the management of patients with cirrhosis and portal hypertension, the current recommendations for the prevention and treatment of variceal bleeding, and outlines the unsolved issues and the perspectives for the future opened by new research developments.

Entities:  

Mesh:

Year:  2008        PMID: 18304681     DOI: 10.1016/j.jhep.2008.01.021

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  70 in total

1.  Percutaneous transhepatic embolization of gastroesophageal varices combined with partial splenic embolization for the treatment of variceal bleeding and hypersplenism.

Authors:  Wei-Dong Gong; Ke Xue; Yuan-Kui Chu; Qing Wang; Wei Yang; Hui Quan; Peng Yang; Zhi-Min Wang; Zhi-Qun Wu
Journal:  Int J Clin Exp Med       Date:  2015-10-15

2.  Management of a Portal Hypertensive Polyp: Case Report of a Rare Entity.

Authors:  Waseem M Seleem; Amr Shaaban Hanafy
Journal:  Gastrointest Tumors       Date:  2019-09-04

3.  Efficacy of carvedilol versus propranolol versus variceal band ligation for primary prevention of variceal bleeding.

Authors:  Ayman Yosry Abd ElRahim; Rabab Fouad; Marwa Khairy; Aisha Elsharkawy; Waleed Fathalah; Haytham Khatamish; Omayma Khorshid; Mona Moussa; Moataz Seyam
Journal:  Hepatol Int       Date:  2017-11-28       Impact factor: 6.047

Review 4.  Angiogenesis and liver fibrosis.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Hepatol       Date:  2015-03-27

Review 5.  Contemporary concepts of the medical therapy of portal hypertension under liver cirrhosis.

Authors:  Dmitry Victorovich Garbuzenko
Journal:  World J Gastroenterol       Date:  2015-05-28       Impact factor: 5.742

6.  Current role of surgery in portal hypertension.

Authors:  Sujoy Pal
Journal:  Indian J Surg       Date:  2011-12-13       Impact factor: 0.656

7.  Hypersplenism is correlated with increased risk of hepatocellular carcinoma in patients with post-hepatitis cirrhosis.

Authors:  Xing Lv; Fan Yang; Xin Guo; Tao Yang; Ti Zhou; Xiaoping Dong; Yong Long; Dan Xiao; Yong Chen
Journal:  Tumour Biol       Date:  2016-01-11

Review 8.  Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications.

Authors:  Sith Siramolpiwat
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

9.  Body composition changes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis.

Authors:  Jonathan Montomoli; Peter Holland-Fischer; Giampaolo Bianchi; Henning Grønbaek; Hendrik Vilstrup; Giulio Marchesini; Marco Zoli
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

10.  Dabigatran Reduces Liver Fibrosis in Thioacetamide-Injured Rats.

Authors:  Kuei-Chuan Lee; Wei-Fan Hsu; Yun-Cheng Hsieh; Che-Chang Chan; Ying-Ying Yang; Yi-Hsiang Huang; Ming-Chih Hou; Han-Chieh Lin
Journal:  Dig Dis Sci       Date:  2018-10-04       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.